BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Schering-Plough Corporation (SGP) Abandons Drug; Ending The Collaboration With ALK-Abello A/S


10/19/2005 5:09:31 PM

KENILWORTH, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported that, after consultation with ALK- Abello, it will not exercise its option agreement related to ALK-Abello's grass-pollen allergy tablet and other non-injectable allergy products. Schering-Plough will focus its research and development resources on other pipeline opportunities. ALK-Abello has reacquired the exclusive worldwide rights to these products, ending the collaboration entered into by the two companies in October 2002.

DISCLOSURE NOTICE: This press release may contain "forward-looking statements" about Schering-Plough's pipeline opportunities and other matters. Forward-looking statements relate to expectations or forecasts of future events. Please carefully consider any forward-looking statement and understand that many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements. Schering-Plough does not assume the obligation to update any forward-looking statement. For further details and a discussion of risks and uncertainties that may affect forward- looking statements, see Schering-Plough's Securities and Exchange Commission (SEC) filings, including Schering-Plough's third quarter 2003 10-Q filed November 7, 2003 and future SEC filings.

Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.

Schering-Plough Corporation

CONTACT: Media, Denise K. Foy, +1-908-298-7616, or Investors, Lisa W.DeBerardine, +1-908-298-7437, both of Schering-Plough Corporation



Read at Reuters
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES